Bio-techne CORP Form 4 insider transactions

James Hippel, CFO of BIO-TECHNE Corp, reported multiple transactions in common stock on July 29, 2026.

Kim Kelderman, Chief Executive Officer and a Director of BIO-TECHNE Corp, reported multiple transactions in common stock on July 28, 2026.

Shane Bohnen, SVP - General Counsel of BIO-TECHNE Corp, reported multiple transactions in common stock on July 23, 2026.

Steven C. Crouse, President of Diagnostics & Spatial Biology at Bio-Techne, reported the vesting and sale of common stock.

Bio-Techne Corp. Director Amy E. Herr reported a sale of 6,636 shares of common stock on May 8, 2026, for approximately $48.28 per share.

CFO James Hippel exercised 62,000 stock options and subsequently withheld 56,955 shares to cover tax obligations.

SVP and General Counsel Shane Bohnen exercised 8,400 stock options and subsequently withheld shares for tax obligations.

CEO Kim Kelderman exercised 26,692 stock options and retained a portion of the resulting shares.

CEO Kim Kelderman exercised 11,344 stock options and retained the resulting shares after a tax-related disposition.

CFO James Hippel exercised 62,000 stock options and sold a portion to cover tax obligations, resulting in a net increase in direct share ownership.

CEO Kim Kelderman exercised 36,500 stock options and withheld 32,088 shares to cover tax obligations.

Shane Bohnen, SVP - General Counsel of Bio-Techne Corp, reported significant stock transactions including the acquisition of 2,259 restricted stock units and the disposal of 740 shares.

Steven C. Crouse, President of Diagnostics & Spatial Biology at Bio-Techne, reported the acquisition of new performance restricted stock units, restricted stock units, and stock options.

Amy E. Herr, a Director at Bio-Techne Corp, reported the sale of 1,976 shares of common stock for approximately $59.11 per share.

BIO-TECHNE Director Amy E. Herr disclosed routine transactions involving common stock and derivative securities, including RSU vesting and tax-related dispositions, executed under a 10b5-1 plan.

Matthew McManus, President of Diagnostics & Spatial Biology at BIO-TECHNE, reported the exercise of restricted stock units and a subsequent sale of shares to cover tax obligations.

BIO-TECHNE Corp's CEO, Kim Kelderman, reported the disposition of 2,303 common shares at $62.57 each to cover tax withholding obligations.

BIO-TECHNE's CFO, James Hippel, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Bio-Techne's President of Protein Sciences, William Geist, reported the vesting of restricted stock units and a subsequent sale of shares for tax purposes.

BIO-TECHNE Director Julie Bushman acquired 1,640 shares of common stock and 3,777 stock options on October 30, 2025, increasing her beneficial ownership.

BIO-TECHNE Director Joseph D. Keegan reported the acquisition of 1,640 shares of common stock and 3,777 stock options, increasing his beneficial ownership.

BIO-TECHNE Director John L. Higgins was granted 1,640 shares of common stock and 3,777 stock options on October 30, 2025.

BIO-TECHNE Director Alpna Seth acquired 1,640 shares of common stock and was granted 3,777 stock options on October 30, 2025.

BIO-TECHNE Director Amy Herr reported the acquisition of 1,640 common shares and 3,777 stock options, alongside existing indirect holdings.

BIO-TECHNE Director Judith V. Klimovsky reported the acquisition of common stock and new stock options, increasing her beneficial ownership.

BIO-TECHNE Director Rupert Vessey acquired 1,640 shares of common stock and 3,777 stock options, increasing his direct beneficial ownership in the company.

BIO-TECHNE Director Robert V. Baumgartner acquired 1,640 shares of common stock and 3,777 stock options on October 30, 2025.

BIO-TECHNE Director Roeland Nusse exercised stock options and subsequently sold an equal number of common shares in a pre-planned transaction.

BIO-TECHNE Director Robert V. Baumgartner exercised stock options and subsequently sold 17,040 shares of common stock.

BIO-TECHNE Corp's CFO, James Hippel, reported a routine acquisition of common stock from RSU vesting and a subsequent disposition of shares for tax withholding purposes.